Rachel Wuerstein, MD

Rachel Würstlein, MD, discusses the use of trastuzumab emtansine following the KAMILLA trial which evaluated the agent in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases.

Rachel Wuerstein, MD, discusses the KAMILLA trial of trastuzumab emtansine in metastatic breast cancer for both a global and Asian cohort.

Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the KAMILLA trial and the benefit of trastuzumab emtansine.